



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/21/000032

To,

M/s Curateq Biologics Private Limited,
SURVEY NO 77 & 78 INDRAKARAN VILLAGE,
SANGA REDDY (India) – 502320.

Sir,

With reference to your application No. GCT/CT04/FF/2021/24542 (GCT/32/21) dated 26-03-2021, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration, Protocol Number: CR213-20, Original, Version 1.0, dated 01/February/2021** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) the Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

- (vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

- (xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,
VENUGOPAL
GIRDHARILA
L SOMANI

GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME
AFFAIRS, ou=CDSCO DGHS,
postalCode=431401, st=Maharashtra,
s.3.4.20=173d03345df6524489632379a
1471bdaae9f0b2bea56c83dbfbc2154e
399b1af7, cn=VENUGOPAL
GIRDHARILAL SOMANI
Date: 2021.09.06 15:24:36 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s Curateq Biologics Private Limited, SURVEY NO 77 & 78 INDRAKARAN VILLAGE, SANGA REDDY (India) – 502320** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: CR213-20, Original, Version 1.0, dated 01/February/2021** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

VENUGOPAL
GIRDHARILA
L SOMANI

Digitally signed by VENUGOPAL GIRDHARILA SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83fbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILA SOMANI
Date: 2021.09.06 15:24:46 +05'30'

(Dr. V. G. Somani)

Drugs Controller General (India)

Central Licencing Authority

Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Ranibizumab 10 mg/mL solution for injection
Therapeutic class:	Ophthalmologicals
Dosage form:	Solution for injection
Composition:	Ranibizumab = 10.0000 mg/ml In House Specification Active
Indications:	Ranibizumab is indicated in adults for:

File No. CT/32/21-DCG(I)

	<ol style="list-style-type: none"> 1. The treatment of neo vascular (wet) age-related macular degeneration (AMD), 2. The treatment of visual impairment due to diabetic macular oedema(DME), 3. The treatment of proliferative diabetic retinopathy(PDR), 4. The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), 5. The treatment of visual impairment due to choroidal neovascularisation (CNV). <p>Ranibizumab is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.</p>
--	---

Annexure:

Details of clinical trial site:

Names and address of clinical trial site	Ethics committee details	Name of investigator
Regional Institute of Ophthalmology, 88, College Street, Kolkata-700073, West Bengal, India	Institutional Ethics Committee Regional Institute of Ophthalmology, 88, College Street, Kolkata-700073, West Bengal, India ECR/59/Inst/WB/2013/RR-19	Dr. Lakshmi Kanta Mondal
BB Eye Foundation VIP, Shree tower II, RAA 36, 2 nd Floor Raghunathpur VIP Road, Kolkata-700059	BB Eye Foundation VIP Ethics Committee, BB Eye Foundation VIP Shree tower II, RAA 36, 2 nd Floor Raghunathpur VIP Road, Kolkata-700059 ECR/1019/Inst/WB/2017	Dr. Rupak Kanti Biswas
Amrita Institute of Medical Sciences and Research Centre, AIMS-Ponekkara. P.O..Kochi - 682041, Kerala, India	Institutional Ethics Committee, Amrita Institute of Medical Sciences, AIMS-Ponekkara, Kochi, Edappally Kerala-682041, India ECR/129/Inst/KL/2013/RR-19	Dr. Natasha Radhakishnan
Dr. Shroff's Charity Eye Hospital, 5027, Kedar Nath Road, Daryaganj, New Delhi-110002, India	Dr. Shroff's Charity Eye Hospital Ethics Committee, Dr. Shroff's Charity Eye Hospital, 5027, Kedar Nath Road, Daryaganj, New Delhi-110002, India ECR/64/Inst/ND/2013/RR-19	Dr. Rahul Mayor

File No. CT/32/21-DCG(I)

AIIMS Bhubaneswar, Sijua, Patrapada, Bhubaneswar-751019, Odisha	Institutional Ethics Committee, AIIMS Bhubaneswar, Sijua, Patrapada, Bhubaneswar-751019, Odisha ECR/534/Inst/OD/2014/RR-20	Dr. Sucheta Parija
Regional Institute of Ophthalmology, SCB Medical College and Hospital, Cuttack-753007, Odisha, India	Institutional Ethics Committee, SCB Medical College and Hospital, Cuttack-753007, Odisha, India ECR/84/Inst/OR/2013/RR-20	Dr. Subhabrata Parida
Rising Retina Clinic, 312-313, Iscon Center, Shivranjani Cross Roads, Satellite, Ahmedabad-380015, Gujarat, India	Medilink Ethics Committee, Basement Medilink Hospital, Nr Shyamal Cross Road, 132 Ft Ring Road, Satellite, Ahmedabad-380015 ECR/344/Inst/GJ/2013/RR-19	Dr. Rohan Ramchandra Chuhan
Shanty Saroj Netralay, A.N. Gaikwad, 901/902, Beside Sundar Nagar, Anand Nursing Home Road, Off, Sangli-Miraj-Rd, Miraj, Maharashtra-416410	IEC-Saishwari Clinic-Hospital for Mental Health, Yashwant Co Op Housing Society Sangli Road, Miraj, Sangli, Maharashtra, India ECR/1245/Inst/MH/2019	Dr. Sharad Bhomaj
L V Prasad Eye Institute, Kode Venkatadri Chowdary Campus, Tadigadapa, Vijayawada-Andhra Pradesh-521137	L V Prasad Eye Institute Ethics Committee, Kallam Anji Reddy campus, L V Prasad Marg Road no; 2, Banjara Hills, Hyderabad, Telangana -500034 ECR/468/Inst/AP/2013/RR-19	Dr. Niroj Kumar Sahoo
Prabhudesai Eye Clinic, Isis, 14, Saket Society, Opp. Siddharth Palace Hall, Near Karishma Society and Joshi Railway Museum, Kothrud, Pune-411038-Maharashtra, India	Ethics Committee of Pulse Multispecialty Hospital, Sr. No, 51/7/B/1, 1 st Floor, Vishwa Arcade, Mumbai-Bangalore Highway, Narhe, Pune-411041 ECR/1339/Inst/MH/2020	Dr. Nitin Prabhudesai
Netralok Retina Clinic, 304-305, Golden Icon, Above Hyundai Showroom, Opp Medilink Hospital, Nr. Shyamal Cross Road, 132 Ft. Ring Road, Satellite, Ahmedabad-380015, Gujarat, India	Sangini Hospital Ethics Committee, C/o Sangini Hospital, First Floor, Santorini Square, B/h Abhishree Complex, Opp. Star Bazar Lane, Satellite, Ahmedabad-380015, Gujarat, India ECR/147/Inst/GJ/2013/RR-19	Dr. Mudit Jitendra Bansal

File No. CT/32/21-DCG(I)

Nandadeep Eye Hospital, Opposite Patidar Bhavan, Madhavnagar Road, Sangli, Maharashtra, India-416416	IEC-Saishwari Clinic-Hospital for Mental Health, Yashwant Co Op Housing Society Sangli Road, Miraj, Sangli, Maharashtra- 416410, India ECR/1245/Inst/MH/2019	Dr. Saurabh Patwardhan
Vision Care Centre Superspeciality Eye Hospital, Sushila Park, Behind Suraj Nagar, Near Panchayat Samiti, Amardham Road Shirur, Dist Pune-412210	EC Vision Care Centre Superspeciality Eye Hospital, Sushila Park, Behind Suraj Nagar, Shirur, Pune, Maharashtra-412210 ECR/1451/Inst/MH/2020	Dr. Swapnil B Bhalekar